Employers Roll Back GLP-1 Coverage for Weight Loss as Exploding Demand and New Oral Options Fuel Cost Concerns
A significant commercial shift is underway in the U.S. employer-sponsored insurance market, as companies begin dropping GLP-1 weight-loss drug coverage due to unsustainable cost projections. Despite falling unit prices driven by the launch of oral alternatives, the sheer volume of patients seeking treatment is forcing major employers—including healthcare giant Cigna—to restrict coverage and push patients toward the cash-pay market.
The Broad Corporate Pullback
Data from major benefits consultancies and policy groups highlight a growing wave of employers planning to eliminate weight-loss drug benefits:
- The 2027 Cliff: Approximately 10% of employers currently covering GLP-1 medications for weight loss plan to drop coverage entirely in 2027, according to a survey by the Business Group on Health. Benefits consultancy Mercer reported that 5% of large employers (500+ employees) plan to drop coverage in 2027.
- Current Coverage Baselines: As of 2026, Mercer reports that 44% of companies with more than 500 employees cover GLP-1s for obesity, while Business Group on Health data shows that 67% of large employers offer the benefit. Consultancies like Aon predict these percentages will contract sharply next year.
- The "Volume Over Unit Cost" Paradox: In 2026, the list and net prices of individual treatments have declined, notably with the launches of Novo Nordisk's oral semaglutide (Wegovy pill) in January and Eli Lilly's oral orforglipron (Foundayo) in April. Both oral options feature cash-pay pricing starting at approximately $149 per month. However, because these needle-free oral options appeal to a much broader pool of patients who were previously untreated, the overall patient population has expanded exponentially, keeping aggregate corporate healthcare costs at record highs.
- Middleman Friction: Employers are increasingly frustrated that their negotiated pharmacy benefit manager (PBM) contracts do not reflect the substantial discounts available in the direct-to-consumer (DTC) or government-negotiated cash markets, prompting some to bypass traditional coverage structures.
Cigna's Symbolic Policy Shift
In a highly influential move, The Cigna Group—which operates health insurer Cigna, health services unit Evernorth, and PBM Express Scripts—announced it will stop covering GLP-1 weight-loss drugs (including Wegovy and Zepbound) in its own employee health plan (covering 67,700 employees, 88% of whom are in the U.S.) effective July 1, 2026.
To manage the transition, Cigna informed employees that they can transition to cash-pay options via manufacturer websites or TrumpRx. These cash-pay purchases will not count toward employee deductibles or out-of-pocket maximums. For weight loss, Cigna's employee plan will now only cover older, significantly less effective generic weight-loss medications (such as phentermine, diethylpropion, benzphetamine, and phendimetrazine). The policy change does not affect Cigna's coverage of GLP-1s for type 2 diabetes.
This decision by a major national health insurer and PBM operator is seen as a bellwether for corporate America, demonstrating that even healthcare-sector employers are struggling to absorb the long-term financial impact of broad GLP-1 coverage.
Verbatim Quotes
- From Reuters (June 11, 2026):
"About 10% of employers who now cover GLP-1 drugs for weight-loss said they planned to drop the drugs in 2027, according to the Business Group on Health, a policy research group for large employers."
- From Reuters (June 11, 2026):
"Demand for the drugs has increased this year due to the oral options, attracting people who have never before tried GLP-1s, which has kept employer costs high, according to five industry experts."
- From Reuters (June 2, 2026):
"Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan effective July 1, according to materials viewed by Reuters on Tuesday."
- From Reuters (June 2, 2026):
"In a document circulated to employees, Cigna suggested those currently using the medications can choose to pay for the drugs with cash through manufacturer sites or TrumpRx."